Curve Therapeutics

Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged. Our Microcycle platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes. We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets

Curve therapeutics operates in the Biotechnology research industry.

Curve therapeutics's revenue is 11m - 100m

Curve therapeutics has 11 - 50 employees.